Literature DB >> 8972038

Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.

L Iacoviello1, M C D'Adamo, K Pawlak, R Polishchuck, T Wollny, W Buczko, M B Donati.   

Abstract

Dermatan sulphates have been shown to inhibit thrombus formation and thrombus growth in different experimental model of venous thrombosis. At variance with heparins, they show a remarkably low haemorrhagic potential. On the other hand, very few data are available on the effect of dermatan sulphates on arterial thrombus formation. We evaluated the effects of a low molecular weight (LMW)-dermatan sulphate, a high molecular weight (HMW)-dermatan sulphate and sulodexide (a mixture of fast-moving heparin fraction and dermatan sulphate) in comparison with LMW- and HMW-heparin, in a model of arterial thrombosis in rats. The insertion of an artificial prosthesis into the abdominal aorta of the animals induced the formation of an occluding thrombus within 2-5 days. The time in which 50% of the loops became occluded (OT50) was also calculated and used to compare the efficacy of the different drug treatments. This was 2.84 days for control animals and 4.25 and 5.80 days for HMW- and LMW-dermatan sulphate, respectively. Neither drug changed the "template" bleeding time, even at higher doses. In contrast, HMW-heparin at doses (8 mg/kg, sc, twice a day) inducing an antithrombotic activity comparable to that of dermatan sulphates, dramatically prolonged the bleeding time. LMW-heparin at the same doses was ineffective. Sulodexide (10 mg/Kg, sc, twice a day) prolonged the occlusion time to the same extent as HMW-heparin (OT50 5.10 vs. 4.14 days), with less an effect on the bleeding time (144 +/- 6 s vs. > 300 s, respectively). Histological examination confirms that the prolongation of occlusion time induced by the drugs is really related to thrombus formation inhibition at the site of arterial wall injury. Acetyl salicylic acid (ASA) (100 mg/kg/day in drinking water as lysine acetylsalicylate) did not modify the effect of Desmin 370 and Sulodexide on both occlusion and bleeding time. However, while it did not increase the antithrombotic activity of HMW-heparin, it significantly prolonged its haemorrhagic effect. In conclusion, dermatan sulphates are effective inhibitors of arterial thrombosis in rats, without inducing bleeding complications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972038

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Alterations of fibrin network structure mediated by dermatan sulfate.

Authors:  Ana María Lauricella; María Mercedes Castañon; Lucía C Kordich; Irene L Quintana
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 2.  Development and use of sulodexide in vascular diseases: implications for treatment.

Authors:  Sergio Coccheri; Ferdinando Mannello
Journal:  Drug Des Devel Ther       Date:  2013-12-24       Impact factor: 4.162

3.  Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism.

Authors:  Gualtiero Palareti; Cristina Legnani; Emilia Antonucci; Serena Zorzi; Angelo A Bignamini; Corrado Lodigiani; Alberto Tosetto; Lorenza Bertù; Vittorio Pengo; Sophie Testa; Walter Ageno; Domenico Prisco; Paolo Prandoni; Daniela Poli
Journal:  Intern Emerg Med       Date:  2020-05-25       Impact factor: 3.397

4.  Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Giuseppe M Andreozzi; Angelo A Bignamini; Giovanni Davì; Gualtiero Palareti; Jiří Matuška; Martin Holý; Katarzyna Pawlaczyk-Gabriel; Andrej Džupina; German Y Sokurenko; Yury P Didenko; Laurentia D Andrei; Gianfranco Lessiani; Adriana Visonà
Journal:  Circulation       Date:  2015-09-25       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.